Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:DWTX NASDAQ:GNPX NYSE:PTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.78-3.0%$0.70$0.38▼$215.31$8.76M0.711.03 million shs114,133 shsDWTXDogwood Therapeutics$4.50-4.3%$4.99$1.62▼$29.28$8.98M1.81.46 million shs47,002 shsGNPXGENPREX$0.29-1.3%$0.28$0.20▼$3.97$9.83M-0.54.19 million shs769,166 shsPTNPalatin Technologies$0.09-44.6%$0.09$0.09▼$2.48$2.45M0.942.28 million shs14.57 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma-3.00%-5.26%-8.97%+91.36%-99.63%DWTXDogwood Therapeutics-4.26%-8.54%-6.05%+5.39%+449,999,900.00%GNPXGENPREX-1.28%+3.43%-4.87%+22.00%-85.92%PTNPalatin Technologies0.00%0.00%0.00%+9,409,900.00%+9,409,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEONAEON Biopharma2.411 of 5 stars3.52.00.00.00.01.71.9DWTXDogwood Therapeutics1.8681 of 5 stars3.50.00.00.02.70.00.6GNPXGENPREX1.3424 of 5 stars0.02.00.04.73.30.00.6PTNPalatin TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0046,351.61% UpsideDWTXDogwood Therapeutics 3.00Buy$10.00122.22% UpsideGNPXGENPREX 0.00N/AN/AN/APTNPalatin Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PTN, GNPX, DWTX, and AEON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/ADWTXDogwood TherapeuticsN/AN/AN/AN/A($7.56) per shareN/AGNPXGENPREXN/AN/AN/AN/A$0.15 per shareN/APTNPalatin Technologies$350K6.99N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M$298.124.31N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)DWTXDogwood Therapeutics-$12.35M-$18.04N/AN/AN/AN/AN/A-34.74%8/6/2025 (Estimated)GNPXGENPREX-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)PTNPalatin TechnologiesN/A-$1.55N/A∞N/AN/AN/AN/AN/ALatest PTN, GNPX, DWTX, and AEON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025N/AAEONAEON Biopharma-$11.51N/AN/AN/AN/AN/A8/8/2025N/AGNPXGENPREX-$0.71N/AN/AN/AN/AN/A5/12/2025Q1 2025GNPXGENPREX-$0.82-$0.26+$0.56-$0.26N/AN/A5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AGNPXGENPREXN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22DWTXDogwood TherapeuticsN/A7.437.43GNPXGENPREXN/A1.941.94PTNPalatin TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%DWTXDogwood Therapeutics9.05%GNPXGENPREX14.05%PTNPalatin Technologies11.50%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%DWTXDogwood Therapeutics3.90%GNPXGENPREX8.47%PTNPalatin Technologies7.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.31 million74.37 millionNot OptionableDWTXDogwood Therapeutics51.91 million1.84 millionN/AGNPXGENPREX2033.15 million30.34 millionNo DataPTNPalatin Technologies3026.01 millionN/AN/APTN, GNPX, DWTX, and AEON HeadlinesRecent News About These CompaniesPalatin Technologies, Inc. (PTN) Q3 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comPalatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...May 15, 2025 | gurufocus.comQ3 2025 Palatin Technologies Inc Earnings Call TranscriptMay 14, 2025 | gurufocus.comPalatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug DevelopmentMay 9, 2025 | nasdaq.comPalatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025May 9, 2025 | prnewswire.comPalatin Technologies Announces Encouraging Pre-Clinical Data Of PL9588 For Glaucoma TreatmentMay 7, 2025 | nasdaq.comPalatin Technologies faces delisting from NYSE American due to low stock priceMay 7, 2025 | in.investing.comPalatin Technologies faces delisting from NYSE American due to low stock priceMay 7, 2025 | in.investing.comNYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)May 7, 2025 | businesswire.comPalatin Expects $11.5 Million Financing to Cure NYSE American Delisting NoticeMay 7, 2025 | prnewswire.comPalatin Technologies Announces Pricing of up to $23 Million Public OfferingMay 7, 2025 | prnewswire.comPalatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma TherapyMay 5, 2025 | prnewswire.comPL9643 shows promise in dry eye disease treatmentApril 30, 2025 | investing.comPalatin Reports Positive Results From Responder Analyses Of Phase 3 MELODY-1 Study In DEDApril 30, 2025 | nasdaq.comPalatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye DiseaseApril 29, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTN, GNPX, DWTX, and AEON Company DescriptionsAEON Biopharma NASDAQ:AEON$0.78 -0.02 (-3.00%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$0.78 +0.01 (+1.29%) As of 07/16/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Dogwood Therapeutics NASDAQ:DWTX$4.50 -0.20 (-4.26%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$4.68 +0.19 (+4.11%) As of 07/16/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.GENPREX NASDAQ:GNPX$0.29 0.00 (-1.28%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$0.29 +0.00 (+0.41%) As of 07/16/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Palatin Technologies NYSE:PTN$0.09 -0.08 (-44.65%) As of 05/7/2025Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
